Ipsen SA

IPN

Company Profile

  • Business description

    Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

  • Contact

    70 rue Balard
    Paris75015
    FRA

    T: +33 158335000

    E: [email protected]

    https://www.ipsen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    5,358

Stocks News & Analysis

stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks

New data centre deal for ASX listed REIT

New parternship adds to a growing data centre pipeline in fiscal 2026.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,035.501.40-0.02%
CAC 408,195.2145.710.56%
DAX 4024,539.3448.930.20%
Dow JONES (US)48,382.39319.100.66%
FTSE 1009,951.1419.760.20%
HKSE26,338.47707.932.76%
NASDAQ23,235.636.36-0.03%
Nikkei 22551,544.011,204.532.39%
NZX 50 Index13,573.1724.750.18%
S&P 5006,858.4712.970.19%
S&P/ASX 2008,727.801.800.02%
SSE Composite Index3,968.843.720.09%

Market Movers